Mitochondria-Targeting Small Molecules Effectively Prevent Cardiotoxicity Induced by Doxorubicin
Overview
Affiliations
Doxorubicin (Dox) is a chemotherapeutic agent widely used for the treatment of numerous cancers. However, the clinical use of Dox is limited by its unwanted cardiotoxicity. Mitochondrial dysfunction has been associated with Dox-induced cardiotoxicity. To mitigate Dox-related cardiotoxicity, considerable successful examples of a variety of small molecules that target mitochondria to modulate Dox-induced cardiotoxicity have appeared in recent years. Here, we review the related literatures and discuss the evidence showing that mitochondria-targeting small molecules are promising cardioprotective agents against Dox-induced cardiac events.
Pal C Cardiovasc Toxicol. 2024; 25(2):216-247.
PMID: 39495464 DOI: 10.1007/s12012-024-09941-7.
Modeling drug-induced mitochondrial toxicity with human primary cardiomyocytes.
Tang X, Liu H, Rao R, Huang Y, Dong M, Xu M Sci China Life Sci. 2023; 67(2):301-319.
PMID: 37864082 DOI: 10.1007/s11427-023-2369-3.
Ding X, Zhang Y, Pan P, Long C, Zhang X, Zhuo L Theranostics. 2023; 13(2):510-530.
PMID: 36632225 PMC: 9830424. DOI: 10.7150/thno.80066.
Mitochondrial-Targeted Therapy for Doxorubicin-Induced Cardiotoxicity.
Wu B, Leung K, Poon E Int J Mol Sci. 2022; 23(3).
PMID: 35163838 PMC: 8837080. DOI: 10.3390/ijms23031912.
Sun L, Wang H, Xu D, Yu S, Zhang L, Li X Bioengineered. 2021; 13(1):48-60.
PMID: 34898356 PMC: 8805895. DOI: 10.1080/21655979.2021.2004980.